Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) Vice President – Drug Discovery Graham Robertson speaks to Proactive following the release of new pre-clinical study results. speaks to Proactive following the release of new pre-clinical study results.
Robertson tells Proactive that the trial was "the first time that this style of drug has been developed to target midkine", a substance in the body that plays a role in the development of cancer.
Robertson suggests that the new drug could one day play a role in inhibiting tumour growth in human patients.